Uterine / Endometrial Cancer

Uterine (endometrial) cancer is the most common gynecologic malignancy in the US. Surgical staging with total hysterectomy and bilateral salpingo-oophorectomy is the cornerstone of treatment. Immunotherapy has transformed advanced and recurrent disease: pembrolizumab plus lenvatinib is standard second-line therapy, and checkpoint inhibitors — pembrolizumab and dostarlimab — produce durable responses in dMMR/MSI-H tumors.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Uterine / Endometrial Cancer

• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Dostarlimab (Jemperli) — Checkpoint Inhibitor
• Lenvatinib (Lenvima) — Tyrosine Kinase Inhibitor
• Carboplatin (Paraplatin) — Alkylating Agent
• Paclitaxel (Taxol) — Taxane